NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction

Nuclear factor erythroid 2-related factor (NRF2) is an important transcription factor in oxidative stress regulation. Overexpression of NRF2 is associated with human breast carcinogenesis, and increased NRF2 mRNA levels predict poor patient outcome for breast cancer. However, the mechanisms linking gain of NRF2 expression and poor prognosis in breast cancer are still unclear. Here, we provide evidence that NRF2 deletion inhibits proliferation and metastasis of breast cancer cells by down-regulating RhoA. Restoration of RhoA in MCF7 and MDA-MB-231 cells induced NRF2 knockdown-suppressed cell growth and metastasis in vitro, and NRF2 silencing suppressed stress fiber and focal adhesion formation leading to decreased cell migration and invasion. Mechanistic studies showed that NRF2 binds to the promoter region of estrogen-related receptor α (ERR1) and may function as a silencer. This may enhance RhoA protein stability and lead to RhoA overexpression in breast cancer cell. Our findings indicate that NRF2 silencing-mediated reduction of RhoA expression contributes, at least in part, to the poor outcome of breast cancer patients with high NRF2 expression.

[1]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[2]  M. Leary,et al.  Genetic and epigenetic aspects of breast cancer progression and therapy. , 2014, Anticancer research.

[3]  M. Zhang,et al.  3-aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as potent Nrf2/ARE inducers in human cancer cells and AOM-DSS treated mice. , 2013, Journal of medicinal chemistry.

[4]  Sergey V Plotnikov,et al.  Guiding cell migration by tugging. , 2013, Current opinion in cell biology.

[5]  W. Zhou,et al.  Drug resistance associates with activation of Nrf2 in MCF‐7/DOX cells, and wogonin reverses it by down‐regulating Nrf2‐mediated cellular defense response , 2013, Molecular carcinogenesis.

[6]  Min Chen,et al.  Dynamic functions of RhoA in tumor cell migration and invasion , 2013, Small GTPases.

[7]  C. Klaassen,et al.  Effect of Graded Nrf2 Activation on Phase-I and -II Drug Metabolizing Enzymes and Transporters in Mouse Liver , 2012, PloS one.

[8]  H. Aburatani,et al.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. , 2012, Cancer cell.

[9]  N. Yoo,et al.  Somatic mutations of the KEAP1 gene in common solid cancers , 2012, Histopathology.

[10]  Young Woo Kim,et al.  E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells , 2012, Journal of Cell Science.

[11]  G. Packham,et al.  Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent , 2012, Cell Stress and Chaperones.

[12]  Tomo Sasaki,et al.  Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice. , 2011, Oncology reports.

[13]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[14]  P. Hordijk,et al.  The role of ubiquitylation and degradation in RhoGTPase signalling , 2010, Journal of Cell Science.

[15]  V. Raman,et al.  Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. , 2010, Carcinogenesis.

[16]  P. Pandolfi,et al.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis , 2010, Nature Cell Biology.

[17]  J. Wikswo,et al.  Increased Cell Migration and Plasticity in Nrf2 Deficient Cancer Cell Lines , 2010, Oncogene.

[18]  C. Geng,et al.  Over Expression of RhoA is Associated with Progression in Invasive Breast Duct Carcinoma , 2010, The breast journal.

[19]  M. Ding,et al.  Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. , 2009, Molecular cell.

[20]  Robert H Insall,et al.  Actin dynamics at the leading edge: from simple machinery to complex networks. , 2009, Developmental cell.

[21]  C. B. Pickett,et al.  The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress* , 2009, Journal of Biological Chemistry.

[22]  M. McMahon,et al.  NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. , 2009, Trends in biochemical sciences.

[23]  Erik Sahai,et al.  The actin cytoskeleton in cancer cell motility , 2009, Clinical & Experimental Metastasis.

[24]  S. Narumiya,et al.  Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion , 2009, Cancer and Metastasis Reviews.

[25]  A. Hall,et al.  DLC1: a significant GAP in the cancer genome. , 2008, Genes & development.

[26]  A. Paradiso,et al.  RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. , 2008, International journal of molecular medicine.

[27]  A. Ridley,et al.  Rho GTPases in cancer cell biology , 2008, FEBS letters.

[28]  John G. Collard,et al.  Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.

[29]  P. Nioi,et al.  A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. , 2007, Biochemical and biophysical research communications.

[30]  K. Hahn,et al.  Spatiotemporal dynamics of RhoA activity in migrating cells , 2006, Nature.

[31]  M. Fleming,et al.  The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity* , 2006, Journal of Biological Chemistry.

[32]  Alan Hall,et al.  Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.

[33]  J. Guerrero,et al.  Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. , 2005, Experimental cell research.

[34]  H. Akaza,et al.  Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis , 2004, Cancer Research.

[35]  M. Monden,et al.  High expression of two genes selected by iAFLP: a new prognostic factor of estrogen receptor-positive breast cancer. , 2004, Oncology reports.

[36]  A. Jaiswal,et al.  Nrf2 signaling in coordinated activation of antioxidant gene expression. , 2004, Free radical biology & medicine.

[37]  Jeffrey A. Johnson,et al.  An important role of Nrf2-ARE pathway in the cellular defense mechanism. , 2004, Journal of biochemistry and molecular biology.

[38]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[39]  K. Burridge,et al.  RhoA and ROCK Promote Migration by Limiting Membrane Protrusions* , 2003, The Journal of Biological Chemistry.

[40]  B. Kaina,et al.  Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters , 2002, British Journal of Cancer.

[41]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[42]  J. Camonis,et al.  Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors , 2001, Journal of Cancer Research and Clinical Oncology.

[43]  M. Kwak,et al.  Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Jaiswal,et al.  Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes , 1998, Oncogene.

[45]  Yoshiharu Matsuura,et al.  Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)* , 1996, The Journal of Biological Chemistry.

[46]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[47]  S. Aaronson,et al.  Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. , 1994, The Journal of biological chemistry.

[48]  W. Linehan,et al.  Examination of human tumors for rhoA mutations. , 1994, Oncogene.

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.